Novartis reports significant proteinuria reduction by Fabhalta in Phase 3 IgAN trial

Novartis has shared encouraging results from the Phase III APPLAUSE-IgAN study, revealing that Fabhalta (iptacopan) led to a significant 38.3% reduction in proteinuria, as measured ... Read More